We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,391

Life sciences: product regulation and liability in Thailand
  • Baker McKenzie
  • Thailand, Global
  • March 19 2018

A structured guide to product regulation and liability laws in Thailand


Efforts to Cut Drug Prices in Medicaid
  • Manatt Phelps & Phillips LLP
  • USA
  • February 27 2018

Over the past five years, the budgets of state Medicaid programs have been challenged by the introduction of new high-cost drugs into the marketplace


Does It Still Cost $2.7B to Develop a Drug? Regardless, Patent Protection is Key!
  • Dilworth IP
  • USA
  • January 23 2018

We have previously reported that the cost to develop a new drug is roughly $2.7B (inflation adjusted). This price tag was determined by the Tufts


Guest Post: Christmas Came Early on December 8 - Favorable Developments in Fosamax & Accutane Litigation
  • Reed Smith LLP
  • USA
  • December 14 2017

This guest post is by Kevin Hara, an associate at Reed Smith and relatively frequent contributor to the Blog. Here, he discusses two recent favorable


Federal Circuit Patent Updates - November 2017
  • Wilmer Cutler Pickering Hale and Dorr LLP
  • USA
  • November 8 2017

Moore, J. Reversing finding of nonobviousness and holding claims invalid as obvious. “The district court clearly erred in finding a skilled artisan


Ready to Release a New Pharmaceutical? What to Think About When Selecting Your Drug Name
  • Foley & Lardner LLP
  • USA
  • November 8 2017

Pharmaceutical name clearance in the United States can be complicated. This post aims to provide insight into the regulatory safety review process and


California Passes Drug Transparency Law with Onerous Reporting Requirements for Manufacturers
  • Arent Fox LLP
  • USA
  • October 20 2017

Following in the steps of Maryland and Nevada, California just adopted a comprehensive drug pricing transparency law that will have a significant


Design Defect Claims Preempted In Eye Drop Litigation
  • Dechert LLP
  • USA
  • October 19 2017

Do as I say, not as I do. A crutch used by parents worldwide to justify their own bad habits while trying to ensure their children don't repeat them


OIG Releases October Work Plan Items; Includes Opioid REMS and Specialty Drug Coverage and Medicare Reimbursement
  • Cooley LLP
  • USA
  • October 17 2017

As we recently announced, the Office of Inspector General (OIG) is updating its Work Plan monthly rather than its previous twice-yearly publications


New California Law Limits Drug Manufacturer Co-Pay Cards and Other Discounts in California
  • Hogan Lovells
  • USA
  • October 16 2017

In the most recent salvo by states eager to show an effort to contain prescription drug costs, California's governor has signed into law a bill that